DiNuzzo Private Wealth’s Haemonetics HAE Stock Holding History

DiNuzzo Private Wealth’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$843	Buy	8 +1	+14%	+$93	﹤0.01%	926
2026 Q2	$525	Buy	7 +4	+133%	+$257	﹤0.01%	1091
2026 Q1	$170	Sell	3 -7	-70%	-$456	﹤0.01%	1251
2025 Q4	$802	Buy	10 +5	+100%	+$336	﹤0.01%	941
2025 Q3	$273	Sell	5 -3	-38%	-$186	﹤0.01%	1225
2025 Q2	$597	Sell	8 -1	-11%	-$66	﹤0.01%	1021
2025 Q1	$572	Sell	9 -1	-10%	-$68	﹤0.01%	1004
2024 Q4	$781	Buy	10 +3	+43%	+$241	﹤0.01%	934
2024 Q3	$563	Sell	7 -2	-22%	-$162	﹤0.01%	1068
2024 Q2	$745	Buy	9 +1	+13%	+$88	﹤0.01%	906
2024 Q1	$683	Sell	8 -2	-20%	-$157	﹤0.01%	867
2023 Q4	$856	Buy	+10	New	+$865	﹤0.01%	768

Other funds holding HAE

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return

Isthmus Partners Madison, Wisconsin $1.04B AUM 19.97% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.36B AUM 20.86% 1-Year Est. Return

VestGen Advisors Inverness, Illinois $3.25B AUM 30.95% 1-Year Est. Return

Cardinal Capital Management Inc (North Carolina) Raleigh, North Carolina $861M AUM 27.19% 1-Year Est. Return

Skylands Capital Milwaukee, Wisconsin $762M AUM 14.92% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

DiNuzzo Private Wealth's HAE Position: Q3 2026 in Review

DiNuzzo Private Wealth increased its Haemonetics (HAE) stake by 14% in Q3 2026, buying an estimated $93 and bringing the position to 8 shares worth $843. The position accounts for ﹤0.01% of the portfolio, ranked #926.

DiNuzzo Private Wealth first reported a position in HAE in Q4 2023 and has held it in 12 quarters since. The position peaked at $856 in Q4 2023. 63 funds tracked by Wall St. Rank hold HAE as of Q3 2026.

DiNuzzo Private Wealth held 8 shares of Haemonetics worth $843 as of Q3 2026.
DiNuzzo Private Wealth bought 1 Haemonetics share in Q3 2026, an estimated $93.
Haemonetics made up ﹤0.01% of DiNuzzo Private Wealth's portfolio in Q3 2026, its #926 holding.
DiNuzzo Private Wealth first reported a position in Haemonetics in Q4 2023 and has held it in 12 quarters since.
DiNuzzo Private Wealth's Haemonetics position peaked at $856 in Q4 2023.
63 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.

Based on DiNuzzo Private Wealth's 13F filing for Q3 2026, filed 16 Oct 2026.